CAD 1.0
(5.26%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 | -14 Thousand CAD | -7.69% |
2023 | -13 Thousand CAD | -8.33% |
2022 | -12 Thousand CAD | 93.06% |
2021 | -173 Thousand CAD | 18.4% |
2020 | -212 Thousand CAD | -278.57% |
2019 | -56 Thousand CAD | 66.47% |
2018 | -167 Thousand CAD | -28.46% |
2017 | -130 Thousand CAD | 2.99% |
2016 | -134 Thousand CAD | 0.0% |
2015 | - CAD | 0.0% |
2014 | - CAD | 0.0% |
2013 | - CAD | -100.0% |
2012 | 2.51 Million CAD | -12.84% |
2011 | 2.89 Million CAD | 4.52% |
2010 | 2.76 Million CAD | 18.92% |
2009 | 2.32 Million CAD | -1.15% |
2008 | 2.35 Million CAD | 2.93% |
2007 | 2.28 Million CAD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q3 | -3000.00 CAD | 0.0% |
2024 Q1 | -4000.00 CAD | 0.0% |
2024 Q4 | -3000.00 CAD | 0.0% |
2024 Q2 | -3000.00 CAD | 25.0% |
2023 Q2 | -3000.00 CAD | 0.0% |
2023 Q1 | -3000.00 CAD | 0.0% |
2023 FY | -13 Thousand CAD | -8.33% |
2023 Q4 | -4000.00 CAD | -33.33% |
2023 Q3 | -3000.00 CAD | 0.0% |
2022 Q4 | -3000.00 CAD | -50.0% |
2022 Q3 | -2000.00 CAD | 33.33% |
2022 Q2 | -3000.00 CAD | 0.0% |
2022 Q1 | -3000.00 CAD | 92.5% |
2022 FY | -12 Thousand CAD | 93.06% |
2021 Q4 | -40 Thousand CAD | 0.0% |
2021 FY | -173 Thousand CAD | 18.4% |
2021 Q3 | -40 Thousand CAD | 0.0% |
2021 Q2 | - CAD | 0.0% |
2021 Q1 | - CAD | 0.0% |
2020 Q4 | - CAD | 0.0% |
2020 FY | -212 Thousand CAD | -278.57% |
2020 Q1 | - CAD | 0.0% |
2020 Q2 | - CAD | 0.0% |
2020 Q3 | - CAD | 0.0% |
2019 Q3 | - CAD | 0.0% |
2019 Q2 | - CAD | 0.0% |
2019 Q1 | - CAD | 0.0% |
2019 FY | -56 Thousand CAD | 66.47% |
2019 Q4 | - CAD | 0.0% |
2018 Q4 | - CAD | 0.0% |
2018 FY | -167 Thousand CAD | -28.46% |
2018 Q3 | - CAD | 0.0% |
2018 Q2 | - CAD | 0.0% |
2018 Q1 | - CAD | 0.0% |
2017 Q1 | 27 Thousand CAD | 0.0% |
2017 FY | -130 Thousand CAD | 2.99% |
2017 Q4 | - CAD | 0.0% |
2017 Q3 | - CAD | 0.0% |
2017 Q2 | - CAD | -100.0% |
2016 Q1 | - CAD | 0.0% |
2016 Q2 | - CAD | 0.0% |
2016 FY | -134 Thousand CAD | 0.0% |
2016 Q4 | - CAD | 0.0% |
2016 Q3 | - CAD | 0.0% |
2015 FY | - CAD | 0.0% |
2015 Q4 | - CAD | 0.0% |
2015 Q3 | - CAD | 0.0% |
2015 Q2 | - CAD | 0.0% |
2015 Q1 | - CAD | 0.0% |
2014 Q1 | - CAD | 0.0% |
2014 Q3 | - CAD | 0.0% |
2014 Q4 | - CAD | 0.0% |
2014 Q2 | - CAD | 0.0% |
2014 FY | - CAD | 0.0% |
2013 Q1 | 527 Thousand CAD | -16.75% |
2013 FY | - CAD | -100.0% |
2013 Q2 | - CAD | -100.0% |
2013 Q4 | - CAD | 0.0% |
2013 Q3 | - CAD | 0.0% |
2012 Q3 | 607 Thousand CAD | -0.98% |
2012 Q4 | 633 Thousand CAD | 4.28% |
2012 FY | 2.51 Million CAD | -12.84% |
2012 Q2 | 613 Thousand CAD | -7.96% |
2012 Q1 | 666 Thousand CAD | 5.05% |
2011 Q4 | 634 Thousand CAD | -2.91% |
2011 FY | 2.89 Million CAD | 4.52% |
2011 Q1 | 791 Thousand CAD | 0.0% |
2011 Q2 | 812 Thousand CAD | 2.65% |
2011 Q3 | 653 Thousand CAD | -19.58% |
2010 FY | 2.76 Million CAD | 18.92% |
2009 FY | 2.32 Million CAD | -1.15% |
2008 FY | 2.35 Million CAD | 2.93% |
2007 FY | 2.28 Million CAD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Appili Therapeutics Inc. | 813.74 Thousand CAD | 101.72% |
Eupraxia Pharmaceuticals Inc. | -209.91 Thousand CAD | 93.331% |
Microbix Biosystems Inc. | 7.48 Million CAD | 100.187% |
Medicenna Therapeutics Corp. | -5000.00 CAD | -180.0% |
Satellos Bioscience Inc. | -8.81 Million CAD | 99.841% |
Oncolytics Biotech Inc. | -403 Thousand CAD | 96.526% |
Sernova Corp. | -445.55 Thousand CAD | 96.858% |